Quantitative molecular diagnostic methods, such as qPCR, can effectively detect pathogen-21 specific nucleic acid sequences. However, costs associated with multi-pathogen quantitative 22 molecular diagnostics hinder their widespread use. Nano-liter qPCR (nL-qPCR) is a miniaturized 23 tool for quantification of multiple targets in large numbers of samples based on assay 24 parallelization on a single chip, with potentially significant cost-savings due to rapid throughput 25 and reduced reagent volumes. We evaluated a suite of novel and published assays to detect 17 26 enteric pathogens using a commercially available nL-qPCR technology. Assay efficiencies 27 ranged from 88-98% (mean 91%) and were reproducible across four operators at two separate 28 facilities. When applied to complex fecal material, assays were sensitive and selective (99.8% of 29 DNA amplified were genes from the target organism). Detection limits were 1-2 orders of 30 magnitude higher for nL-qPCR than an existing enteric TaqMan Array Card (TAC), due to 31 nanofluidic volumes. Compared to the TAC, nL-qPCR displayed 97% (95% CI 0.96, 0.98) negative 32 percent agreement and 63% (95% CI 0.60, 0.66) overall positive percent agreement. Positive 33 percent agreement was 90% for target concentrations above the nL-qPCR detection limits. nL-34 qPCR assays showed an underestimation bias of 0.34 log 10 copies/gram of stool [IQR -0.41, -35 0.28] compared with the enteric TAC. Higher detection limits, inherent to nL-qPCR, do not 36 hinder detection of clinically relevant pathogen concentrations. With 12 times higher 37 throughput for a sixth of the per-sample cost of the enteric TAC, the nL-qPCR chip described 38 here is a viable alternative for enteropathogen quantification for studies where other 39 technologies are cost-prohibitive. 40 41 range. Intra-assay precision (repeatability) was measured within-chip and between chips. 130
Introduction 42
Quantitative molecular diagnostic methods, such as quantitative polymerase chain 43 reaction (qPCR), can target nucleic acid gene sequences specific to known microbial pathogens. 44
These methods have provided insights in the study of diarrheal disease beyond what can be 45 gained using microbiological cell culture or immunoassays (1-4) and have been applied 46 successfully in the field of pathogen detection for decades (5) (6) (7) (8) (9) . Over time, molecular 47 diagnostics were developed from single-gene qPCR assays to multiplex reactions (10) (11) (12) (13) (14) and to 48 multi-assay, multi-sample arrays that can be operated in parallel on a single chip or card (15-49 19) . Specifically in the field of enteric pathogen detection, a TaqMan Array Card (TAC) was 50 developed by Liu and colleagues (15, 16 ) and subsequently used in several studies to estimate 51 pathogen-attributable diarrhea burdens (3, 4, 20) , as well as the impact of enteric pathogens on 52 child growth (21-23) and vaccine uptake (24, 25) . However, despite advances in the throughput 53 of molecular detection of pathogens, costs associated with broad multi-target molecular assays 54 still pose a barrier to their widespread use in epidemiological studies. For instance, the per-55 sample cost of the enteric TAC is $60-155, not including labor, capital equipment, nor DNA 56 extraction reagents (15) . 57
Compared with TaqMan qPCR arrays, higher-throughput microfluidic qPCR technologies 58 hold potential to decrease per sample costs of multi-target diagnostics. In the case of nano-liter 59 (nL) qPCR, precision robotic dispensing permits smaller reaction volumes, increases throughput, 60 and reduces reagent volumes. While nL-qPCR technologies have been previously applied to 61 pathogen detection, early efforts to develop nL-qPCR pathogen chips were limited by factors 62 such as: (i) high-detection limits associated with small reaction volumes (6-33 nL), (ii) 63 insufficient assay validation, and (iii) relatively low sample throughput per chip (12-48 samples) 64 (26) (27) (28) . 65
In more recent studies, a commercial nL-qPCR technology (SmartChip™ Real-Time PCR, 66 TakaraBio Inc.) was used to design multi-target diagnostics to detect the presence of antibiotic 67 resistance genes in urban wastewater treatment plant effluent, reclaimed water, and 68 environmental samples (29) (30) (31) and to evaluate a suite of related dehalogenase genes in 69 complex microbial communities (32). This technology uses 100 nL reaction volumes and allows 70 for flexible configuration of a 5184-well chip that can analyze up to 384 samples (depending on 71 the number of assays included). Using this platform, we developed a nL-qPCR chip with 54 72 assays (targeting 17 enteric pathogens) across 96 samples in duplicate. Here, we present 73 comprehensive validation of the technology with laboratory standards as well as fecal samples 74 from children in rural Bangladesh. The nL-qPCR enteropathogen chip permits high-throughput, 75 rapid pathogen detection at significantly lower cost per-sample than other methods. 76 77 Methods 78
Assay design 79
We selected bacterial, protozoan, and helminthic enteropathogens identified as 80 contributing to diarrheal disease in children across twelve countries (33, 34) . We 81 computationally designed and screened 175,000 candidate primer pairs to target 16 virulence 82 genes using methods described previously (32) . Briefly, amino acid sequences corresponding to 83 all non-redundant members of each target gene's protein family (Pfam v 27.0) were clustered 84 based on percent pairwise identity using BLASTp all-vs-all search (35) . We downloaded 85 corresponding nucleotide sequences from NCBI, and DNA oligonucleotide primers were 86 designed to target conserved DNA-level sequence motifs in sequence clusters containing the 87 target virulence protein for each pathogen. A Python script directed the software primer3 (36) 88 to develop thousands of candidate primer pairs for each target gene, which were then screened 89 in silico against other non-target clusters within the same protein family. Up to eight assays per 90 target gene were selected for laboratory screening. We included an additional 10 published 91 assays (see Table 1 ) to assess the suitability for inclusion of previously validated assays 92 optimized at similar PCR conditions (15, (37) (38) (39) (40) (41) Duplicate chips were run, using the standard TakaraBio protocol: 95°C for 3 min, then 40 cycles 102 of (95°C for 60s, 60°C for 70s). We excluded assays that reproducibly displayed fluorescence in 103 the negative control (PCR grade water) prior to cycle 28, failed to amplify standards at 100 104 copies per well, or had PCR efficiencies less than 85%. Final assays were selected based on 105 optimal performance characteristics as described below. Each chip contained a minimum of 106 two negative (no-template) controls for each assay. 107 108
Analytical performance characteristics 109
Analytical performance was evaluated in accordance with the Minimum Information for 110
Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines (42). Assay 111 efficiencies were evaluated with a pool of synthetic DNA standards, described above. Standards 112 were 10-fold serially diluted (10 to 10 6 copies/reaction). Standard curves were run on a 113 minimum of 15 chips over two instruments at separate facilities (Fremont, CA and East Lansing, 114 MI) and with two different operators at each location. Efficiencies were calculated according to 115
Rutledge and Côté (43); mean efficiency over all runs is reported along with coefficient of 116 variation (CV). Limit of detection (LOD) was determined with pooled synthetic DNA standards 117 spiked into extracted DNA from 10 fecal samples to a final concentration of 10, 100, and 1000 118 copies/reaction; then each sample was run in duplicate on two separate chips. The mean cycle 119 quantification (C q ) value (i.e. the cycle at which sufficient copies of target DNA have been made 120 to produce a fluorescent signal detectable by the instrument) was calculated for duplicate 121 assays on a single chip, and all results under the C q cutoff of 30 were determined positive. A 122 total of 20 positive samples (10 samples x 2 chips) per target at each concentration were 123 assayed and LOD is defined as the lowest concentration which 95% were positively detected 124 (i.e. where 19 of the 20 were detected). 125
Inter-assay precision (reproducibility) was assessed across the standard curves used for 126 efficiency calculations measured over 15-20 chips, using different lots of master mix, different 127 batches of oligonucleotide primers, and 4 different operators at 2 separate facilities. We report 128 the mean CV on calculated copy numbers over all points on the standard curve as well as the 129 Sensitivity and specificity were evaluated using four pools of DNA standards, spiked into 140 extracted DNA from 40 pathogen-free fecal samples. For each pathogen 10 samples contained 141 the target at low concentration (100 copies/reaction), 10 samples at medium concentration 142 (10x the LOD) and 10 samples at high concentration (100x the LOD); an additional 10 samples 143 had no target. Sensitivity and specificity were determined based on positive or negative 144 detection in these 40 samples. In order to further verify assay specificity, we sequenced PCR 145 amplicons obtained from running 96 child fecal samples on the nL-qPCR chip. The Seq-Ready ™ 146 TE MultiSample FLEX protocol, PCR clean-up, and DNA quantification prior to sequencing were 147 done in accordance with TakaraBio's standard procedures, as described previously (Atshemyan, 148 2017; Firtina, 2017) . The resulting paired-end Illumina MiSeq reads were quality filtered and 149 only sequences that were the expected target gene amplicon length (+/-3 bp) were 150 maintained. We verified the intended target (organism and gene) by conducting a nucleotide 151 BLAST search (35) on each unique sequence. We retained the top hit(s), defined as the highest 152 sequence identity with the lowest E value. 153 154
Sample collection 155
To test the performance of nL-qPCR chip and against the performance of enteric TAC in 156 epidemiology-relevant samples, we utilized 254 fecal samples from children in rural 157
Bangladesh. Children were between 10 and 18 months old and enrolled in the WASH Benefits 158 randomized controlled trail (44-47). Split samples from these children had been previously 159 assayed for pathogens with the TAC technology (manuscript in preparation). 
Statistical analyses 171
Data analysis was performed in R statistical software (v3.5.2) and analysis files are 172 available as supplemental files. CV, the standard deviation of replicates divided by the mean, 173 was used to evaluate precision in accordance with the MIQE guidelines (42). Specifically, CV of 174 calculated copy number, and not C q value, is reported per Schmittgen and Livak (48) and 175 Hellemans et al. (49) . Within-chip, between-chip, and between instrument/operator variances 176 were compared with a pairwise Wilcoxon rank sum test, using the Benjamini-Hochberg 177 procedure to account for multiple comparisons (50). Sensitivity and specificity were calculated 178 using the epi.test function from the epiR package (51). Positive percent agreement and 179 negative percent agreement were calculated in the same manner and are reported with this 180 alternative nomenclature as recommended when no known reference standard is used (52). 181
Exact binomial 95% confidence limits on sensitivity and specificity were calculated according to 182 Collett (53) . Unweighted Cohen's Kappa was calculated using the epi.kappa function with 183 confidence intervals calculated according to Rothman (54). Bias in calculated log 10 copy 184 numbers per gram of stool (corrected for extraction and PCR efficiency by normalizing to the 185 positive control PhHV spike-in) was evaluated according to Bland and Altman (55) using the 186 blandr::blandr.statistics function to estimate bias (56); 95% confidence intervals determined 187 per Bland and Altman (57) . 188 189
Data Availability and Cost Estimates 190
Nucleotide sequences obtained from Bangladeshi child fecal samples for the specificity 191 analysis are deposited in the Sequence Read Archive under BioProject # SUB5519617. Cost 192 estimates for both nL-qPCR and TAC qPCR technologies can be found in Table S1 . 193
Results 195

Analytical performance 196
The mean efficiency for each assay, based on the evaluation of standard curves run on 15-197 20 chips, ranged from 88-98% (mean 91%) with a coefficient of variation of 6.3% [IQR 5.3, 198 7.3]( Table 2) . The linearity over all assays on all chips was 0.990 [IQR 0.987, 0.992] and 199 detection limits were between 10-100 copies/100nL reaction, which corresponds to 8x10 5 -200 8x10 6 copies/g of stool (Table 2) . Within-chip repeatability was assessed in ten replicates on a 201 single chip: synthetic DNA in high (10 5 copies/reaction) and low (10 2 copies/reaction) 202 concentrations was spiked into DNA extracted from fecal samples. The high concentration 203
displayed a coefficient of variation in calculated copy number of 15% [IQR 8 -25]); the low 204 concentration had variability of 27% [IQR 18 -36] ( Figure S1 ). 205 C q values across replicate chips were highly repeatable for synthetic DNA standards (R 2 = 206 0.989, Figure 1a ), for synthetic DNA in a complex stool DNA matrix (R 2 = 0.984, Figure 1b 1c) across all assays, which corresponds to a coefficient of variation on calculated gene copy 210 number of 28% [IQR 16 -50] ( Table 2 , Repeatability). The highest variability was again seen at 211 the lowest concentrations ( Figure S2 ). 212
Assays were reproducible across two instruments and four operators, again with an inverse 213 relationship noted between variance and concentration (Table S2 ). At concentrations one or 214 more orders of magnitude above the detection limit, coefficient of variation on calculated copy 215 number ranged from 17 -44% ( Table 2) . Coefficient of variation at the limit of detection ranged 216 from 29% to 115% for pathogen virulence and marker genes, the highest of which was 217 analogous to 17 ± 20 copies detected. The highest variance (319%) observed was for the total 218 bacterial (16S rRNA) assay at the detection limit of 10 copies/reaction. Between-chip variance 219 was similar to variance across two instruments and four operators (p = 0.99) but both were 220 significantly higher than within-chip variance (p < 0.0001, pairwise Wilcoxon rank sum test). 221
Coefficients of variation of the magnitudes observed are not biologically relevant when 222 analyzing pathogen quantities on the log 10 scale, as is the normal procedure. 223
Analytical sensitivity ranged from 98-100% and specificity from 90-100% (Table 2 ) 224 among 60 samples containing combinations of synthetic nucleic acid spiked into DNA extracted 225 from 15 different individuals and assayed in duplicate. To further ensure the specificity of the 226 assays, we sequenced amplicons from 96 fecal samples collected from children in Bangladesh 227 that tested positive for at least one pathogen target. We obtained 1.7M (26,747 unique) 228 sequences with 330 [IQR 142, 1171] unique sequences per assay. Amplicon sequencing showed 229 that the assays were specific. The intended gene target was correctly identified in the top hit(s) 230
(defined as highest identity and lowest E value) for 99.8% of unique sequences. Most (99.7%) of 231 the BLASTn searches returned a database top hit with ≥97% sequence identity. The Ascaris 232 lumbricoides assay had highest number of off-target hits: 7/130 of the unique sequences were 233 identified as the same target gene in a closely related species, Ascaris ovis. 234 235
Clinical performance 236
We analyzed 254 fecal samples collected from children in Bangladesh on both the nL-237 qPCR chip and the TAC to compare performance. Overall percent agreement was 90% for the 238 >4500 reactions and negative percent agreement was 97% (95% CI 0.96, 0.98)(Cohen's Kappa = 239 0.66 (95% CI 0.63 -0.69)). Positive percent agreement was highly dependent on concentration 240 of the target gene. At concentrations above nL-qPCR detection limits (>10 7 copies/g stool) 241
positive percent agreement was 90%; this dropped to 62% for concentrations near the nL-qPCR 242 detection limits (10 5 -10 7 copies/ g stool) and fell to 8% for concentrations below 10 5 copies/g 243 stool. In instances where both methods detected the presence of target genes, nL-qPCR assays 244 displayed a median underestimation bias of -0.34 log 10 copies [IQR -0.41, -0.28] (see Table 3 245
and Figure S3 for individual assay statistics). 246
Reactions detected by TAC but not by nL-qPCR were typically below nL-qPCR detection 247 limits, with TAC C q values approximately 30.9 [IQR 28.6, 33.0] (Figure 2a , black points). The 248 higher detection limits for nL-qPCR assays did not interfere with detection of diarrhea-causing 249 pathogen concentrations, with the exception of the V. cholerae assay which had an etiologic 250 cutoff that was below the nL-qPCR detection limit. The etiologic cutoff (shown as red lines in 251 Figure 2a ) indicates the TAC C q value below which children were highly likely to have diarrhea, 252
i.e. the value at which the odds ratio for diarrhea cases compared to controls was greater than 253 2 (Liu, 2016 , Platts-Mills, 2018 . nL-qPCR assays detected all but 8 of the 40 reactions in which 254 TAC assays detected a sample below the etiologic C q cutoff value (3 of which were for V. 255 cholerae), and typically detected samples well above the cutoff for most assays (Figure 2a ). 256
Reactions positive by nL-qPCR but not TAC were also at low concentrations ( Figure 2b ) and 257 could have been the result of less stringent amplification without the use of probe-based dyes 258 with nL-qPCR. 259
Contamination may cause false-positive qPCR results, and can occur due to cross-260 contamination between samples or as a result of free ambient DNA in the laboratory 261 environment. Sample cross-contamination occurred rarely with nL-qPCR; amplification of 262 pathogen virulence or marker genes in no-template controls occurred in <3% of the 4288 no-263 template control sample reactions. Moreover, these amplifications resulted in calculated copy 264 numbers near or below the established limit of detection (median 35 [IQR 28 -42] calculated 265 copies). Ambient laboratory contamination was detected more frequently. Amplification of 266 bacterial 16S rRNA occurred in 46% of no-template controls, and was highly dependent on 267 operator. In all cases, contamination was near the detection limit with 11 [IQR 7, 25] The primary difference in performance we observed was that a majority of the nL-qPCR 280 assays had detection limits 1-2 orders of magnitude higher than TAC. This was due to reactions 281 that utilize 16 times less sample volume (0.0125 µL compared to 0.2-0.4 µL for TAC; 282 (15,personal communication with J. Liu, 2019) . Furthermore, among 254 fecal samples from 283 Bangladeshi children 14 months old, most nL-qPCR assays displayed an underestimation bias 284 (i.e. returned a lower estimated number of copies per gram of stool) compared to the enteric 285 TAC. However, these differences do not appear to be limitations in terms of ability to 286 distinguish pathogen loads relevant for diarrheal disease for pathogens with etiological cutoffs 287 established, with the potential exception of infection with Vibrio cholerae. Importantly, the TAC 288 and nL-qPCR assays for V. cholerae target different virulence genes: hemolysin (hlyA) for TAC 289 and toxin-coregulated pilus (tcpA) for nL-qPCR. The etiologic cutoffs were established for hlyA, 290
which is commonly detected in environmental V. cholerae strains that lack both the tcpA and 291 cholera toxin genes (58). Thus, discordant detection between the technologies might not 292 represent differences in performance, but rather differential presence of these virulence genes 293 within V. cholerae strains. Given that studies have shown low concentrations of V. cholerae hlyA 294 gene are observed in feces coincident with diarrheal symptoms in children (3, 4) , this might be 295 a superior gene target for V. cholerae in pathogen panels. Additional studies should verify the 296 optimal gene target for diarrhea-causing V. cholerae species. 297
298
In studies where quantitation is required at lower concentrations than were achieved in 299 this study, pre-amplification can be performed as described by Ishii et. al. (28) . In addition, pre-300 printing primers directly onto chips, similar to the TAC spotting procedure, can reduce 301 detection limits by nearly 50%. However, a major advantage of the nL-qPCR SmartChip™ is the 302 flexibility of the platform. Therefore, if a research team does opt to pre-print primers onto 303 chips, we suggest also maintaining a stock of unprinted chips on-hand. The current 304 configuration of the chip was designed with large-scale epidemiology studies in mind, thus 305 increased throughput was prioritized over the inclusion of a higher number of assays. However, 306 researchers wishing to focus on a smaller set of targets can evaluate more samples per plate 307
(further reducing per-sample costs), or the number of samples can be reduced to accommodate 308 an increased number of assay targets. In large-scale studies, replicating analysis for 309 questionable samples is often necessary (e.g. when replicates give discordant results). 310
Unprinted chips allow for an operator to run a limited suite of sample/assay pairs that need to 311 be reanalyzed: for example, 384 samples with questionable results in the initial run from a large 312 study could be analyzed against a minimal suite of 12 assays on a specially designed chip at the 313 end of the study. This facilitates the resolution of discordant results and minimizes missing 314 values in the final dataset, which will maximize statistical power in the analysis stage. 315
316
Unprinted nL-qPCR chips also allow end-users to substitute assays from the ones that 317 we publish here, with appropriate assay validation. This evaluation included 10 pre-published 318 assays that operate at similar PCR conditions, and found they performed well in nL format, 319 suggesting end users have flexibility in re-designing the chip. We further show that seven 320 primer pairs previously validated using TaqMan with probe-based dyes had excellent specificity 321 among 96 fecal samples when utilized with SYBR Green intercalating dye instead. These results 322 suggest the additional reagent costs associated with probes is not necessary to achieve high 323 specificity and is consistent with other findings that have reported equal or superior specificity 324 with SYBR Green compared to TaqMan chemistry (59, 60) . 325
Quantifying nucleic acid targets for large numbers of samples is costly, regardless of the 327 platform used, and recommended best practices are sometimes sacrificed in the face of limited 328 budgets. For example, technical replicates are generally encouraged to facilitate identification 329 of outlier or spurious results, particularly on chip-or card-style platforms, and increase the 330 likelihood of detection near the detection limit where analytical precision is the lowest (15, 61, 331 62). The nL-qPCR pathogen chip is configured to provide duplicate results for the 24 pathogen-332 specific virulence and marker genes. This was deliberate as it is impossible to determine a 333 priori if a sample will be near the detection limit, particularly in the case of fecal samples where 334 the presence of PCR inhibitors is likely (63, 64). Early versions of the enteric TAC included 335 replicates (15), but those have been replaced by additional pathogen targets in latter versions 336 currently in use for large-scale studies (3, 4) . Due to the flexibility in configuration of the nL-337 qPCR, up to 13 additional pathogen targets could be added without sacrificing duplicate assays, 338 and throughput would still be 8-9 times higher and cost 50% less than the enteric TAC. The 339 lower per-sample cost reduces the temptation to compromise best practices in the face of 340 budgetary constraints. 341
342
The nL-qPCR platform has important limitations. First, due to the open chip technology, 343 there is higher likelihood for contamination if not used in a controlled laboratory with minimal 344 ambient contamination and meticulous operators. nL-qPCR does not appear to be well-suited 345 for absolute quantification of total bacteria due to the fact that general bacterial contamination 346 (via 16S rRNA) was detected in almost half of the no-template control samples, albeit at 347 concentrations near the detection limit. To ensure potential low-concentration contamination 348 is identified, we strongly recommend incorporation of replicates when using this technology or 349 more stringent C q filtering (e.g. C q 28 or lower). Another limitation of the current configuration 350 is the omission of viral enteric pathogen targets. The primary aim for this study was to validate 351 the nL-qPCR technology for bacterial and parasitic targets, and we expect that future iterations 352 of the chip will include viral targets, which could be combined with a reverse-transcriptase 353 protocol for the study of RNA as well as DNA viruses. 354
In conclusion, we found the nL-qPCR pathogen chip to be an acceptable alternative to 355 other methods; particularly for studies with large numbers of samples as savings in both cost 356 and time will be amplified at scale. 357
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